Quantcast
Last updated on April 16, 2014 at 21:24 EDT

Latest Lilly Stories

2013-09-09 23:01:50

On-the-record National Press Club event will feature local families and leaders from United Nations Foundation and the Women’s Philanthropy Institute at Indiana University Lilly Family School of Philanthropy (PRWEB) September 09, 2013 On Thursday, at 12:00 pm ET at the National Press Club, the United Nations Foundation and the Women’s Philanthropy Institute at Indiana University Lilly Family School of Philanthropy will launch a new report on the charitable habits of children. The new...

2013-08-29 12:25:45

Companies embark on evidence-based research effort to advance health care outcomes LOUISVILLE, Ky. and INDIANAPOLIS, Aug. 29, 2013 /PRNewswire/ -- Humana Inc. (NYSE: HUM), one of the nation's leading health and well-being companies, and Eli Lilly and Company (NYSE: LLY), a leading, innovation-driven corporation, today announced a joint research collaboration aimed at improving the health care of their members and patients. Under the partnership, the companies will utilize their expertise and...

2013-08-28 08:26:10

INDIANAPOLIS, Aug. 28, 2013 /PRNewswire/ -- The Board of Directors of Eli Lilly and Company (NYSE: LLY) has elected Marschall S. Runge, M.D., Ph.D., as a new member, effective September 1, 2013. Dr. Runge, 59, is the Executive Dean for the School of Medicine at the University of North Carolina at Chapel Hill (UNC). As a member of Lilly's board, Dr. Runge will serve on the Science and Technology Committee and the Public Policy and Compliance Committee. "I am very pleased to welcome...

2013-08-01 08:28:22

First-of-its-kind program aims to help improve diversity in clinical trials INDIANAPOLIS and BUFFALO, N.Y., Aug. 1, 2013 /PRNewswire/ -- In an effort to increase the number of minority investigators in clinical research, Eli Lilly and Company (NYSE: LLY) and The Center for Drug Development and Clinical Trials at Roswell Park Cancer Institute (RPCI) today announced a new collaborative training program specifically tailored to this growing group of investigators. This program is the...

2013-07-31 08:30:04

Boehringer Ingelheim and Lilly initiate post-marketing trial with a planned enrollment of more than 8,000 adults with type 2 diabetes in 24 countries RIDGEFIELD, Conn. and INDIANAPOLIS, July 31, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company (NYSE: LLY) today announced enrollment of the first patient into a cardiovascular (CV) and renal outcomes trial for linagliptin (TRADJENTA) tablets. The CARMELINA(1) (CArdiovascular Safety &...

2013-07-24 08:29:13

INDIANAPOLIS, July 24, 2013 /PRNewswire/ -- Worldwide revenue increased 6 percent as growth in key products offset lower Zyprexa revenue following patent expirations in most major markets. Cymbalta sales increased 22 percent while Cialis increased 13 percent. Higher revenue and ongoing cost containment drove strong earnings growth. Second quarter earnings per share grew to $1.11 (reported), or $1.16 (non-GAAP). 2013 earnings per share guidance range raised to $4.28 - $4.38...

2013-07-23 16:24:28

TORONTO, July 23, 2013 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) today announced the exclusive licensing of worldwide rights to a novel small molecule transcriptional regulator ("TT-601") from Eli Lilly and Company for the treatment of osteoarthritis ("OA") pain.  TT-601 is a potent and selective ligand for a novel nuclear receptor target. Modulating the activity of this novel target in patients with osteoarthritis may...

2013-07-17 12:27:19

INDIANAPOLIS, July 17, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its financial results for the second quarter of 2013 on Wednesday, July 24, 2013. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance. The conference call will be held from 9:00 a.m. to 10:00 a.m. EDT. Investors, media and the general public can access a live webcast of the conference call...

2013-07-08 08:26:50

INDIANAPOLIS, July 8, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced that John C. Lechleiter, Ph.D., has returned to his duties as chairman, president, and chief executive officer. Lechleiter has been on medical leave since his scheduled surgery for a dilated aorta on May 13, 2013. Lechleiter's surgery and recovery were successful and he has been cleared by his personal physician and the company's employee health services physician to return to full-time work....

2013-07-08 08:26:46

European Medicines Agency accepted companies' marketing authorisation application INDIANAPOLIS, and INGELHEIM, Germany, July 8, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim today announced that the companies' marketing authorisation application (MAA) for LY2963016, an investigational basal (long-acting) insulin for the treatment of type 1 and type 2 diabetes, has been accepted for review by the European Medicines Agency (EMA). LY2963016 is a new...